BioSpace News Archive

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission.

Codex DNA, Inc. today announced the launch of its public offering of 6.7 million shares of its common stock.

Predictive Oncology Inc. today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of an aggregate of 15,520,911 shares of its common stock.

The Global medical equipment maintenance market is expected to reach US$ 36,525.26 Mn in 2027 from US$ 16,943.29 Mn in 2018.

The report highlights the trends prevalent in the global hair transplant market and the factors driving the market along with those that act as deterrents to its growth.

The rising number of patients suffering with diabetes and adoption of injection pens over traditional syringes and vials is expected to increase the demand for pen needles over the forecast period.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

AXON NEUROSCIENCE SE (“Axon”), a clinical stage biotech company at the forefront of treating and preventing Alzheimer’s disease announced today the publication in Nature Aging of results from its completed Phase II study ADAMANT evaluating its tau vaccine AADvac1 against Alzheimer’s disease

Enochian BioSciences, Inc. announced that it has entered into a definitive securities purchase agreement with several institutional investors for the issuance and sale of an aggregate of 3,866,667 shares of its common stock at a purchase price of $7.50 per share of common stock a registered direct offering priced at-the-market under Nasdaq rules.

BridgeBio Pharma, Inc. announced that on June 1, 2021, the compensation committee of BridgeBio’s board of directors granted 21 new employees restricted stock units for an aggregate of 47,963 shares of the Company’s common stock.